Samuel Waxman Cancer Research Foundation (SWCRF) adds distinguished cancer researchers to its scientific advisory board.

 

Drs. Steven D. Gore of the Yale School of Medicine, and Ramon Parsons of the Icahn School of Medicine at Mount Sinai join SWCRF’s brain trust of scientists from leading research institutes.


Steven D. Gore, M.D. Ramon Parsons, M.D., Ph.D.
Yale School of Medicine Icahn Shool of Medicine at Mount Sinai

 

The Samuel Waxman Cancer Research Foundation (SWCRF) announced the addition of two renowned cancer researchers, Steven D. Gore, M.D., Director of Hematologic Malignancies at Yale Cancer Center and Clinical Program Leader for Hematology at Smilow Cancer Hospital at Yale-New Haven, and  Ramon Parsons, M.D., Ph.D., Professor and Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai, to its Scientific Advisory Board (SAB).

Drs. Gore and Parsons will join their fellow SWCRF SAB members at the Waxman Foundation’s upcoming scientific review and symposium to evaluate progress reports from the foundation’s funded researchers as part of the SWCRF’s annual grant renewal process. The SWCRF SAB, which, together with the foundation’s scientific leadership, approves grant proposals submitted by cancer researchers from NCI-designated research institutes, includes Lorraine Gudas, Ph.D., Chair of Pharmacology at Weill Cornell Medical Center, Nancy Speck, Ph.D., Professor of Cell and Developmental Biology at the University of Pennsylvania, and Hua Yu, Ph.D., Professor of Cancer Immunotherapeutics and Tumor Immunology, City of Hope NCI Comprehensive Cancer Center.

The SWCRF’s scientific leadership includes Samuel Waxman, M.D., Founder and CEO, Jonathan D. Licht, M.D., Chief of the Division of Hematology/Oncology Division at the Feinberg School of Medicine at Northwestern University, who is SWCRF’s Chief Scientific Officer, and Alan G. Rosmarin, M.D., Chief of Hematology/Oncology at UMass Memorial Cancer Center of Excellence, who is SWCRF’s Chief Mission Officer. 

“It is our great pleasure to welcome Steven Gore and Ramon Parsons to our Scientific Advisory Board,” said SWCRF founder and CEO Samuel Waxman, M.D. “Together, they will contribute the expertise of an impressive body of work in cancer research that will be a huge asset to our mission to foster breakthrough cancer science.” 

Scheduled for May 3 and 4 at the Leon and Norma Hess Center for Science and Medicine at The Mount Sinai Hospital, the SWCRF’s annual scientific review and symposium brings together the Institute Without Walls, a network of the foundation’s funded scientists working collaboratively throughout the United States and abroad on research projects that identify and correct abnormal gene function that causes cancer and develop minimally toxic patient treatments. The network includes scientists from leading cancer research institutions, including Dana-Farber Cancer Institute, Johns Hopkins University, Memorial Sloan-Kettering Cancer Center, Icahn School of Medicine at Mount Sinai and Weill Cornell Medical Center, among many others. 

About Steven Gore, M.D.

Prior to joining Yale University in 2013, Dr. Steven Gore served for 23 years on the faculty of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in the Division of Hematologic Malignancies and was a member of the Leukemia Program. He has been recognized as a leader in clinical and translational research in myeloid malignancies, including myelodysplastic syndrome and acute promyelocytic leukemia.  His work was recognized as a Stohlman Scholar of the Leukemia and Lymphoma Society.  He is a member of the Leukemia Core Committee and Leukemia Laboratory Committee of the Eastern Cooperative Oncology Group.  He has led multicenter and cooperative group protocols in myelodysplastic syndrome and acute promyelocytic leukemia, including the first randomized trial comparing the impact of the addition of a histone deacetylase inhibitor to a DNA methyltransferase inhibitor in myelodysplastic syndrome.  He founded and has chaired the five biannual International Workshops on the Clinical Translation of Epigenetic Therapy in Cancer Therapeutics.  In November 2013 he became Director of Hematologic Malignancies at Yale Cancer Center and Clinical Program Leader of the Hematology Program at Smilow Cancer Hospital at Yale-New Haven.  He continues close collaboration with colleagues at Johns Hopkins.

About Ramon Parsons, M.D.

Dr. Ramon Parsons joined the faculty at the Icahn School of Medicine at Mount Sinai in 2013 as Ward-Coleman Professor in Cancer Research, Chairman of the Department of Oncological Sciences and co-Leader of the Cancer Mechanisms Program of the Tisch Cancer Institute where he studies cancer signaling and biology with an emphasis on breast cancer. Prior to joining the faculty at ISMMS, Dr. Parsons was the Avon Professor of Pathology and Medicine and Leader of the Breast Cancer Program of the Herbert Irving Cancer Center at Columbia University Medical Center. Dr. Parsons is a member of the American Society for Clinical Investigation and the American Association of Physicians. He is also a Komen Scholar and the recipient of the 2011 American Association for Cancer Research Outstanding Investigator Award for Breast Cancer Research.  He currently serves as the Chair of the Special Conferences Committee at the AACR.

About Samuel Waxman Cancer Research Foundation

The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research and its mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer. This research is the basis of developing minimally toxic treatments for patients. Through the Foundation’s collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since its inception in 1976, the Samuel Waxman Cancer Research Foundation has awarded more than $85 million to support the work of more than 200 researchers across the globe. For more information, visit: www.waxmancancer.org